**Table S3: Clinical characteristics of the DILI groups and healthy subjects in Center 2.**

| Characteristics | **Total DILI (*n*=21)** | **Group Ⅰ**  **0~6 M DILI (*n*=15)** | **Group Ⅱ**  **>6 M DILI (*n=*6)** | **Healthy subjects**  **(n=14)** | **Ⅰ vs Ⅱ**  ***P* value** |
| --- | --- | --- | --- | --- | --- |
| **Median age / Year (25, P75)** | 60 (45, 69) | 54.00 (42, 68) | 68 (58, 72) | 39  (31, 47) | 0.139 |
| **Female / n (%)** | 13 (66.7) | 10 (66.7) | 3 (50.0) | 5 (35.7) | 0.488 |
| **ALT / U·L-1 (P25, P75)** | 155.00 (103.00, 531.00) | 266.00 (109.00, 651.00) | 139.00 (89.05, 256.00) | 29.38 (12.56, 46.20) | 0.243 |
| **AST / U·L-1 (P25, P75)** | 135.00 (65.00, 239.00) | 135.00 (64.00, 248.00) | 121.00 (65.00, 256.00) | 24.0  (20.0,29.5) | 0.846 |
| **ALP / U·L-1 (P25, P75)** | 111.00 (80.50, 170.00) | 101.00 (80.00, 182.00) | 134.00 (102.00, 165.00) | 64.83 (34.75, 94.91) | 0.414 |
| **TBil / µmol·L-1 (P25, P75)** | 34.80 (17.00, 98.00) | 36.60 (12.60, 128.00) | 25.85 (27.80, 66.70) | 11.49  (6.32, 16.66) | 0.876 |
| **INR / IU (P25, P75)** | 1.03 (0.97, 1.07) | 1.02 (0.93, 1.07) | 1.06 (1.05, 1.07) | 0.9  (0.7, 1.1) | 0.146 |
| **IgG / g·L-1 (P25, P75)** | 12.98 (10.54, 13.99) | 11.25 (8.07, 15.38) | 13.90 (13.21, 14.02) | 12.31  (8.23, 15.6) | 0.088 |
| **IgM / g·L-1 (P25, P75)** | 1.06 (0.67, 1.48) | 1.33 (0.86, 1.48) | 0.72 (0.48, 1.44) | 1.43  (0.6, 2.1) | 0.461 |
| **Positive rate of autoantibody\* / %** | 23.8 | 20.0 | 33.3 | 0 | 0.316 |

\* Positive rate of autoantibodies included antinuclear antibodies, smooth muscle antibodies, antimitochondrial antibodies and anti-parietal cell antibodies; *P* value: 0~6 M DILI *vs* >6 M DILI.